Western pharmaceutical companies are looking into alternative suppliers after the release of a draft U.S. legislation that is seeking to restrict a Chinese drug developer and manufacturer over national security concerns, Oliver Barnes, Ian Johnston, and Eleanor Olcott of The Financial Times says. The Biosecure Act would prohibit U.S. companies receiving federal grant money from working with four Chinese biotech companies, including WuXi AppTec and WuXi Biologics. Eli-Lilly (LLY), Vertex Pharmaceuticals (VRTX), and BeiGene (BGNE), among others, have been discussing with rival contract manufacturers to diversify production, several people familiar with discussions said. ArriVent BioPharma (AVBP) and Dianthus Therapeutics (DNTH) are also exploring alternative manufacturing options.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Amphastar Pharmaceuticals (NASDAQ:AMPH) Offers Savvy Value Investors a Window of Opportunity
- Eli Lilly sees Q1 pre-tax IPR&D charges of roughly $111M
- Viking Therapeutics Stock (NASDAQ:VKTX): Analysts Stay Bullish on 2024’s Top Mid-Cap
- LLY, REGN, BHVN: Which Biotech Stock Offers the Most Upside?
- Lilly weight loss drug on limited supply through April, FDA says